Can't fault the Chinese! Played us like a fiddle. Will be painful in 15 years if Karara is operating and profitable! I've lost a stack of cash on this one. Lesson learnt.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%